KIT and Melanoma: Biological Insights and Clinical Implications

키워드

참고문헌 (91)

1. Besmer P, "A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family", Nature, 320, pp.415~421 (1986)
2. Yarden Y, "Human proto-oncogene c-kit : a new cell surface receptor tyrosine kinase for an unidentified ligand", EMBO J, 6, pp.3341~3351 (1987)
3. Antonescu CR, "The GIST paradigm : lessons for other kinase-driven cancers", J Pathol, 223, pp.251~261 (2011)
4. Lemmon MA, "A new twist in the transmembrane signaling tool-kit", Cell, 130, pp.213~215 (2007)
5. d’Auriol L, "Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4", Hum Genet, 78, pp.374~376 (1988)
6. Qiu FH, "Primary structure of c-kit : relationship with the CSF-1", PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus, 1988, pp.7, 1003~1011
7. Crosier PS, "Expression of isoforms of the human receptor tyrosine kinase ckit in leukemic cell lines and acute myeloid leukemia", Blood, 82, pp.1151~1158 (1993)
8. Reith AD, "Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase", EMBO J, 10, pp.2451~2459 (1991)
9. Zhu WM, "Alternate splicing creates two forms of the human kit protein", Leuk Lymphoma, 12, pp.441~447 (1994)
10. Chen SQ, "The progress and implication of stem cell factor", Basic Med Sci Clin, 22, pp.385~390 (2002)
11. Philo JS, "Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, Kit", J Biol Chem, 271, pp.6895~6902 (1996)
12. Lemmon MA, "Kit receptor dimerization is driven by bivalent binding of stem cell factor", J Biol Chem, 272, pp.6311~6317 (1997)
13. Yuzawa S, "Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor", Cell, 130, pp.323~334 (2007)
14. Hendriks RW, "Drug discovery : new Btk inhibitor holds promise", Nat Chem Biol, 7, pp.4~5 (2011)
15. Sansal I, "The biology and clinical relevance of the PTEN tumor suppressor pathway", J Clin Oncol, 22, pp.2954~2963 (2004)
16. Silva CM, "Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis", Oncogene, 23, pp.8017~8023 (2004)
17. Summy JM, "Treatment for advanced tumors : SRC reclaims center stage", Clin Cancer Res, 12, pp.1398~1401 (2006)
18. Yasuda T, "Regulation of lymphocyte fate by Ras", ERK signals, 2008, pp.7, 3634~3640
19. Kitamura Y, "Kit as a human oncogenic tyrosine kinase", Cell Mol Life Sci, 61, pp.2924~2931 (2004)
20. Kuang D, "Stem cell factor", c-kit signaling mediated cardiac stem cell migration via activation of p38 MAPK, 2008, pp.103, 265~273
21. Liang J, "The Ckit receptor-mediated signal transduction and tumor-related diseases", Int J Biol Sci, 9, pp.435~443 (2013)
22. Stankov K, "C-KIT signaling in cancer treatment", Curr Pharm Des, 20, pp.2849~2880 (2014)
23. Sun J, "Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit", J Biol Chem, 283, pp.27444~27451 (2008)
24. Brunet A, "Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor", Cell, 96, pp.857~868 (1999)
25. Datta SR, "Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery", Cell, 91, pp.231~241 (1997)
26. Dhandapani KM, "Neuroprotection by stem cell factor in rat cortical neurons involves AKT and NFkappaB", J Neurochem, 95, pp.9~19 (2005)
27. Yang E, "Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death", Cell, 80, pp.285~291 (1995)
28. Jeon S, "Stem cell factor induces ERM proteins phosphorylation through PI3K activation to mediate melanocyte proliferation and migration", Pigment Cell Melanoma Res, 22, pp.77~85 (2009)
29. Han DC, "The Grb7 family proteins : structure, interactions with other signaling molecules and potential cellular functions", Oncogene, 20, pp.6315~6321 (2001)
30. Thömmes K, "Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit", stem cell factor receptor, 1999, pp.341(Pt 1), 211~216
31. Jahn T, "Role for the adaptor protein Grb10 in the activation of Akt", Mol Cell Biol, 22, pp.979~991 (2002)
32. Sattler M, "Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL)", J Biol Chem, 272, pp.10248~10253 (1997)
33. van Dijk TB, "Stem cell factor induces phosphatidylinositol 3'-kinase-dependent Lyn", Tec, Blood, pp.2000, 96[DOI]
34. Takaki S, "Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk", J Exp Med, 195, pp.151~160 (2002)
35. Drube S, "The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells", Blood, 115, pp.3899~3906 (2010)
36. Wu H, "Interaction of the erythropoietin and stem-cell-factor receptors", Nature, 377, pp.242~246 (1995)
37. Jahn T, "Direct interaction between Kit and the interleukin-7 receptor", Blood, 110, pp.1840~1847 (2007)
38. Anzai N, "C-kit associated with the transmembrane 4 superfamily proteins constitutes a functionally distinct subunit in human hematopoietic progenitors", Blood, 99, pp.4413~4421 (2002)
39. Corless CL, "Biology of gastrointestinal stromal tumors", J Clin Oncol, 22, pp.3813~3825 (2004)
40. Maulik G, "Modulation of c-Kit", SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer, 2004, pp.23, 237~251
41. Heinrich MC, "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor", J Clin Oncol, 21, pp.4342~4349 (2003)
42. Joensuu H, "The management of gastrointestinal stromal tumors : a model for targeted and multidisciplinary therapy of malignancy", Annu Rev Med, 63, pp.247~258 (2012)
43. Berger MF, "Melanoma genome sequencing reveals frequent PREX2 mutations", Nature, 485, pp.502~506 (2012)
44. Carvajal RD, "KIT as a therapeutic target in metastatic melanoma", JAMA, 305, pp.2327~2334 (2011)
45. Cerami E, "The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)
46. Curtin JA, "Somatic activation of KIT in distinct subtypes of melanoma", J Clin Oncol, 24, pp.4340~4346 (2006)
47. Gao J, "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal", Sci Signal, 6, pp.pl1~ (2013)
48. Hodis E, "A landscape of driver mutations in melanoma", Cell, 150, pp.251~263 (2012)
49. Hugo W, "Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma", Cell, 165, pp.35~44 (2016)
50. Krauthammer M, "Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma", Nat Genet, 44, pp.1006~1014 (2012)
51. Liang WS, "Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma", Genome Res, 27, pp.524~532 (2017)
52. Shain AH, "Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway", Nat Genet, 47, pp.1194~1199 (2015)
53. Snyder A, "Genetic basis for clinical response to CTLA-4 blockade in melanoma", N Engl J Med, 371, pp.2189~2199 (2014)
54. Van Allen EM, "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma", Science, 350, pp.207~211 (2015)
55. Shtivelman E, "Pathways and therapeutic targets in melanoma", Oncotarget, 5, pp.1701~1752 (2014)
56. Carvajal RD, "Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition", Clin Cancer Res, 21, pp.2289~2296 (2015)
57. Gong HZ, "The clinical significance of KIT mutations in melanoma : a meta-analysis", Melanoma Res, 28, pp.259~270 (2018)
58. Heinrich MC, "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor", Blood, 96, pp.925~932 (2000)
59. Tuveson DA, "STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein : biological and clinical implications", Oncogene, 20, pp.5054~5058 (2001)
60. Guo J, "Phase II, openlabel, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification", J Clin Oncol, 29, pp.2904~2909 (2011)
61. Hodi FS, "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin", J Clin Oncol, 31, pp.3182~3190 (2013)
62. Wei X, "Efficacy evaluation of imatinib for the treatment of melanoma : evidence from a retrospective study", Oncol Res, 27, pp.495~501 (2019)
63. Cullinane C, "Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model", Mol Cancer Ther, 9, pp.1461~1468 (2010)
64. Cho JH, "Nilotinib in patients with metastatic melanoma harboring KIT gene aberration", Invest New Drugs, 30, pp.2008~2014 (2012)
65. Delyon J, "STAT3 mediates nilotinib response in KIT-altered melanoma : a phase II multicenter trial of the French Skin Cancer Network", J Invest Dermatol, 138, pp.58~67 (2018)
66. Guo J, "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma : final results from the global, single-arm, phase II TEAM trial", Ann Oncol, 28, pp.1380~1387 (2017)
67. Lee SJ, "Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration : a multicenter trial of Korean Cancer Study Group(UN10-06)", Oncologist, 20, pp.1312~1319 (2015)
68. Lombardo LJ, "Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide(BMS-354825), a dual Src", Abl kinase inhibitor with potent antitumor activity in preclinical assays, 2004, pp.47, 6658~6661
69. Kalinsky K, "A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma : a trial of the ECOG-ACRIN Cancer Research Group(E2607)", Cancer, 123, pp.2688~2697 (2017)
70. Kluger HM, "A phase 2 trial of dasatinib in advanced melanoma", Cancer, 117, pp.2202~2208 (2011)
71. Decoster L, "Biomarker analysis in a phase II study of sunitinib in patients with advanced melanoma", Anticancer Res, 35, pp.6893~6899 (2015)
72. Minor DR, "Sunitinib therapy for melanoma patients with KIT mutations", Clin Cancer Res, 18, pp.1457~1463 (2012)
73. Prosvicova J, "Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases : a case report", Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 159, pp.695~697 (2015)
74. Quintás-Cardama A, "Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib", Nat Clin Pract Oncol, 5, pp.737~740 (2008)
75. Chen Z, "Epigenetic regulation of cardiac progenitor cells marker c-kit by stromal cell derived factor-1α", PLoS One, 8, pp.e69134~ (2013)
76. Lyberg K, "Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis", Oncotarget, 8, pp.9647~9659 (2017)
77. Janostiak R, "Loss of c-KIT expression in breast cancer correlates with malignant transformation of breast epithelium and is mediated by KIT gene promoter DNA hypermethylation", Exp Mol Pathol, 105, pp.41~49 (2018)
78. Chao WR, "Unusual c-KIT+ squamous cell carcinoma of the uterine cervix showing paradoxical hypermethylation of the c-KIT proto-oncogene", Eur J Obstet Gynecol Reprod Biol, 184, pp.130~131 (2015)
79. Chang SW, "A promising hypothesis of c-KIT methylation", expression paradox in c-KIT(+)squamous cell carcinoma of uterine cervix-----CTCF transcriptional repressor regulates c-KIT proto-oncogene expression, 2015, pp.10, 207~
80. Syed SA, "240 Epigenetic regulation of kit expression in murine KitLow interstitial cell of cajal stem cells(ICC-SC)and KitLow gastrointestinal stromal tumor(GIST)cells by polycomb group(PcG)repressive complexes(PRC)", Gastroenterology (2013)
81. Dahl C, "KIT is a frequent target for epigenetic silencing in cutaneous melanoma", J Invest Dermatol, 135, pp.516~524 (2015)
82. Isabel Zhu Y, "Expression of c-kit(CD117)in Spitz nevus and malignant melanoma", J Cutan Pathol, 33, pp.33~37 (2006)
83. Montone KT, "Proto-oncogene c-kit expression in malignant melanoma : protein loss with tumor progression", Mod Pathol, 10, pp.939~944 (1997)
84. Shen SS, "Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array", J Cutan Pathol, 30, pp.539~547 (2003)
85. Ecsedi S, "DNA methylation characteristics of primary melanomas with distinct biological behaviour", PLoS One, 9, pp.e96612~ (2014)
86. Felicetti F, "The promyelocytic leukemia zinc finger-microRNA-221", -222 pathway controls melanoma progression through multiple oncogenic mechanisms, 2008, pp.68, 2745~2754
87. Bell RE, "Enhancer methylation dynamics contribute to cancer plasticity and patient mortality", Genome Res, 26, pp.601~611 (2016)
88. Balachandran VP, "Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido", Nat Med, 17, pp.1094~1100 (2011)
89. Seifert AM, "PD-1", PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors, 2017, pp.23, 454~465
90. Lee KC, "Lck is a key target of imatinib and dasatinib in T-cell activation", Leukemia, 24, pp.896~900 (2010)
91. Kreutzman A, "Mono", oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy, 2010, pp.116, 772~782

관련 논문AI추천